Subarachnoid Hemorrhage - Pipeline Insight, 2024

This “Subarachnoid Hemorrhage- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Subarachnoid Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Subarachnoid Hemorrhage: Understanding

Subarachnoid Hemorrhage: Overview

A subarachnoid hemorrhage means that there is bleeding in the space that surrounds the brain. Most often, it occurs when a weak area in a blood vessel (aneurysm) on the surface of the brain bursts and leaks. The blood then builds up around the brain and inside the skull increasing pressure on the brain. This can cause brain cell damage, life-long complications, and disabilities. A subarachnoid hemorrhage may occur as a complication of a type of stroke called a hemorrhagic stroke, or bleeding inside the brain. This is different from an ischemic stroke, which is caused by a blood clot. This bleeding can sometimes cut through the brain tissue and leak into the area outside the brain (called the subarachnoid space). This is called a subarachnoid hemorrhage and can be life threatening. The blood from the hemorrhage can compress or displace vital brain tissue. A severe hemorrhage can cause a coma, or leave the patient paralyzed. Common symptoms of a subarachnoid hemorrhage include: Loss of consciousness, double vision, nausea or vomiting, severe headache, trouble speaking, drooping eyelid, confusion and trouble concentrating. If patient have symptoms of a subarachnoid hemorrhage, a doctor might use several tests to diagnose it: MRI scan. This test uses large magnets, radiofrequency energy, and a computer to make detailed images of the brain. CT scan-This test uses X-rays and computer technology to make horizontal, or axial images (often called slices) of the brain. CT scans are more detailed than general X-rays. Angiogram-During this test, dye is injected in the blood vessel and then X-rays are taken to evaluate blood flow through them. Spinal tap-In this test, a special needle is placed into the lower back, into the spinal canal. The pressure in the spinal canal and brain can be measured. A small amount of cerebrospinal fluid can be removed and analyzed for the presence of blood. A diagnosis of a cerebral aneurysm isn't usually made until a subarachnoid hemorrhage has already occurred. A subarachnoid hemorrhage is a medical emergency. Immediate treatment is essential to help reduce the risk for permanent brain damage. The main goal of treating a subarachnoid hemorrhage is to stop the bleeding. Often, a doctor may do surgery to place a small clip on the blood vessel to stop blood from leaking into the brain. After a subarachnoid hemorrhage, serious complications can occur. Swelling in the brain, or hydrocephalus, is one of the potential complications. This is caused by the buildup of cerebrospinal fluid and blood between the brain and skull, which can increase the pressure on the brain. Subarachnoid hemorrhage can also irritate and damage the brain's other blood vessels, causing them to tighten - this reduces blood flow to the brain. As blood flow becomes affected, another stroke can result, leading to even further brain damage. In serious cases, the bleeding may cause permanent brain damage, paralysis, or coma.

Subarachnoid Hemorrhage- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Subarachnoid Hemorrhage pipeline landscape is provided which includes the disease overview and Subarachnoid Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Subarachnoid Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Subarachnoid Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Subarachnoid Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Subarachnoid Hemorrhage.

Subarachnoid Hemorrhage Emerging Drugs Chapters

This segment of the Subarachnoid Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Subarachnoid Hemorrhage Emerging Drugs

Nicardipine: BIT Pharma Gmb HBIT Pharma is developing Nica Plant® for patients affected by aneurysmal subarachnoid hemorrhage (a SAH), who are undergoing aneurysm closure by means of microsurgical application of a clip (clipping).Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment ofAneurysmalSubarachnoidHemorrhage.

GTX 104: Acasti Pharma GTX-104 is a clinical stage, novel nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine. This nimodipine injectable formulation is comprised of a nimodipine base, an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection. GTX-104 is an aqueous solution substantially free of organic solvents, such that the nimodipine is contained in a concentrated injection solution, suspension, emulsion or complex as a micelle, a colloidal particle or an inclusion complex, and the formulation is stable andclear.

NP 10679: NeurOp NeurOp is developing NP10679 as a subunit-specific NMDA receptor inhibitor for CNS disorders. NMDA receptors are activated by the neurotransmitter glutamate, the predominant excitatory transmitter in the brain. Several neurological disorders, including pain, treatment-resistant depression and brain damage resulting from acute brain injury, such as stroke or SAH, are associated with overactivity of these receptors. NP10679 is selective for a specific NMDA subtype, GluN2B, and has increased potency in acidic conditions. Its enhanced selectivity and disease context-dependent target engagement may provide neuroprotection with fewer negative side effects than currently available NMDAinhibitors.

Subarachnoid Hemorrhage: Therapeutic Assessment

This segment of the report provides insights about the different Subarachnoid Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Subarachnoid Hemorrhage

There are approx. 10+ key companies which are developing the therapies for Subarachnoid Hemorrhage. The companies which have their Subarachnoid Hemorrhage drug candidates in the most advanced stage, i.e. Phase II include, BIT Pharma GmbH.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Subarachnoid Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Subarachnoid Hemorrhage: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Subarachnoid Hemorrhage therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Subarachnoid Hemorrhage drugs.

Subarachnoid Hemorrhage Report Insights

• Subarachnoid Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Subarachnoid Hemorrhage Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Subarachnoid Hemorrhage drugs?
• How many Subarachnoid Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Subarachnoid Hemorrhage?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Subarachnoid Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Subarachnoid Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BIT Pharma GmbH
• Acasti Pharma
• NeurOp
• CSL Behring
• Avilex Pharma
• Carlsson Research AB

Key Products

• GTX 104
• Nicardipine
• NP 10679
• CSL 888
• AVLX-144
• OSU 6162
• Dexmedetomidine

This product will be delivered within 2 business days.